Literature DB >> 15884110

Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection.

Zarko Babic1, Ivna Svoboda-Beusan, Nastja Kucisec-Tepes, Dragan Dekaris, Rosana Troskot.   

Abstract

AIM: To determine whether local antibiotic resistance involves P-glycoprotein (Pgp)-mediated active drug out-pumping during Helicobacter pylori (H pylori) infection treatment with classic antibiotic therapy.
METHODS: Pgp activity was determined in gastric mucosa biopsy specimens obtained from 53 patients with pathohistologically verified gastritis and microbiologically confirmed H pylori infection, and compared with the Pgp activity in 12 control subjects with normal endoscopic findings. The H pylori positive patients were treated with short-term 7-d therapy consisting of two antibiotics (amoxicillin and azithromycin/metronidazole and clarithromycin) and a proton pump inhibitor. Pgp activity was determined by flow cytometry in the test of rhodamine dye efflux and quantified as mean fluorescence ratio (RMF).
RESULTS: Upon the first cycle, H pylori was successfully eradicated in 20 patients, whereas therapy was continued in 33 patients. In the course of antibiotic therapy, RMF increased (P<0.05) and gastric cells showed higher rhodamine dye efflux. The mean pre-treatment RMF values were also higher (P<0.0001) in patients with multiple therapeutic failure than in those with successful H pylori eradication and control subjects.
CONCLUSION: Pgp might be one of the causes of therapy failure in patients with H pylori and antibiotic therapy could be chosen and followed up on the basis of the Pgp transporter local activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15884110      PMCID: PMC4305904          DOI: 10.3748/wjg.v11.i18.2720

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

Review 1.  The human ATP-binding cassette (ABC) transporter superfamily.

Authors:  M Dean; A Rzhetsky; R Allikmets
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

2.  Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms.

Authors:  T R De Kievit; M D Parkins; R J Gillis; R Srikumar; H Ceri; K Poole; B H Iglewski; D G Storey
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris.

Authors:  J P Marie; S Huet; A M Faussat; J Y Perrot; S Chevillard; V Barbu; C Bayle; J Boutonnat; F Calvo; L Campos-Guyotat; P Colosetti; J L Cazin; P de Cremoux; C Delvincourt; C Demur; B Drenou; O Fenneteau; J Feuillard; A Garnier-Suillerot; P Genne; M C Gorisse; P Gosselin; H Jouault; R Lacave; J Robert
Journal:  Leukemia       Date:  1997-07       Impact factor: 11.528

4.  Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia.

Authors:  H J Broxterman; J Lankelma; H M Pinedo; C A Eekman; D C Währer; G J Ossenkoppele; G J Schuurhuis
Journal:  Leukemia       Date:  1997-07       Impact factor: 11.528

Review 5.  The physiological function of drug-transporting P-glycoproteins.

Authors:  A H Schinkel
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

6.  Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.

Authors:  B L Leu; J D Huang
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori.

Authors:  A Pilotto; G Leandro; M Franceschi; M Rassu; L Bozzola; F Furlan; F Di Mario; G Valerio
Journal:  Aliment Pharmacol Ther       Date:  1999-05       Impact factor: 8.171

8.  Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.

Authors:  L J van Doorn; P M Schneeberger; N Nouhan; A P Plaisier; W G Quint; W A de Boer
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

9.  Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin.

Authors:  S D Georgopoulos; S D Ladas; S Karatapanis; A Mentis; C Spiliadi; V Artikis; S A Raptis
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

10.  The E test for antimicrobial susceptibility testing of Helicobacter pylori.

Authors:  G Cederbrant; G Kahlmeter; A Ljungh
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

View more
  4 in total

Review 1.  Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.

Authors:  Susan M Abdel-Rahman; Gordon L Amidon; Ajay Kaul; Viera Lukacova; Alexander A Vinks; Gregory T Knipp
Journal:  Clin Ther       Date:  2012-11       Impact factor: 3.393

Review 2.  High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.

Authors:  Mei Zhang
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

3.  The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats.

Authors:  Noor Safwah Damanhuri; Endang Kumolosasi; Marhanis Salihah Omar; Amirul Faiz Abd Razak; Ahmad Hasnan Mansor
Journal:  Daru       Date:  2021-01-06       Impact factor: 3.117

4.  Streptococcus agalactiae disrupts P-glycoprotein function in brain endothelial cells.

Authors:  Brandon J Kim; Maura A McDonagh; Liwen Deng; Benjamin D Gastfriend; Alexandra Schubert-Unkmeir; Kelly S Doran; Eric V Shusta
Journal:  Fluids Barriers CNS       Date:  2019-08-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.